Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase EARLY_PHASE1 2

Status

Recruiting 2Completed 2Withdrawn 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 5Other hematologic neoplasm 1

Conditions

Lymphoma, B-Cell 2Motor Activity 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia 1Advanced B-cell Lymphoid Malignancies 1

Interventions

Cyclophosphamide 886Rituximab 864Vincristine 382Etoposide 381fludarabine 342Cytarabine 341Doxorubicin 340fludarabine phosphate 319Methotrexate 310Dexamethasone 283Prednisone 282Lenalidomide 245Filgrastim 228Melphalan 200Peripheral Blood Stem Cell Transplantation 184Radiotherapy 175Whole-Body Irradiation 172Busulfan 165Mycophenolic Acid 161venetoclax 158Bendamustine Hydrochloride 158Granulocyte Colony-Stimulating Factor 151Tacrolimus 145ibrutinib 144Bortezomib 138obinutuzumab 125Gemcitabine 113Cyclosporine 110Antilymphocyte Serum 103Carmustine 100

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × Roflumilast × Lymphoid × Clear all
NCT06643221 2026-06-05

Allo-X

University of Arizona

Phase EARLY_PHASE1 Recruiting
200 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Motor Activity

NCT06977711 2025-08-05

Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)

The University of Texas Health Science Center at San Antonio

Phase 1 Recruiting
10 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT05796271 2024-02-29

Clinical Trial of Roflumilast Added to Standard Chemoimmunotherapy

The University of Texas Health Science Center at San Antonio

Phase 1 Withdrawn
Lymphoid

Lymphoma, B-Cell

NCT03458546 2024-02-21

Study of Roflumilast in Combination With Standard Chemotherapy for High-risk Diffuse Large B-cell Lymphoma

The University of Texas Health Science Center at San Antonio

Phase 1 Completed
14 enrolled
Lymphoid

Lymphoma, B-Cell

NCT01888952 2017-02-27

Phase 0/1 Biomarker and Pharmacodynamic Study of Roflumilast in Patients With Advanced B-Cell Hematologic Malignancies (CTRC# 13-0013)

The University of Texas Health Science Center at San Antonio

Phase EARLY_PHASE1 Completed
10 enrolled 4 charts
Lymphoid

Advanced B-cell Lymphoid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡